About Provexis
Provexis is a company based in Reading (United Kingdom) founded in 1999.. The company has 2 employees as of March 31, 2023. Provexis operates in a competitive market with competitors including GOLO, Cooke Pharma, Errekappa Euroterapici, Lycodha and Essential IP, among others.
- Headquarter Reading, United Kingdom
- Employees 2 as on 31 Mar, 2023
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
- Legal Name Provexis Plc
-
Annual Revenue
$1.67 M (USD)61.13as on Mar 31, 2025
-
Net Profit
$-586.11 K (USD)22.78as on Mar 31, 2025
-
EBITDA
$-580.42 K (USD)25.14as on Mar 31, 2025
-
Latest Funding Round
-
Investors
dsm-firmenich
& 1 more
-
Employee Count
2
as on Mar 31, 2023
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Provexis
Provexis is a publicly listed company on the LSE with ticker symbol PXS in UK, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Unlock access to complete
Unlock access to complete
Funding Insights of Provexis
- Total Funding Total Funding
- Total Rounds 3
- Last Round Last Round
- First Round First Round
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar, 2010 | Amount | Post-IPO - Provexis | Valuation |
investors |
|
| Aug, 2008 | Amount | Post-IPO - Provexis | Valuation |
investors |
|
| Jun, 2002 | Amount | Unspecified - Provexis | Valuation | Enterprise Ventures |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Provexis
Provexis has secured backing from 2 investors, including institutional and venture fund investors. Prominent investors backing the company include dsm-firmenich and Enterprise Ventures. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early and Growth stage Venture Debt firm that does debt investments in the UK
|
Founded Year | Domain | Location | |
|
Health, nutrition, and bioscience solutions are delivered worldwide.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Provexis
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Provexis
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Provexis Comparisons
Competitors of Provexis
Provexis operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GOLO, Cooke Pharma, Errekappa Euroterapici, Lycodha and Essential IP, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Dietary supplements for weight loss are provided by GOLO.
|
|
| domain | founded_year | HQ Location |
Medical food for angina and cardiovascular conditions is developed.
|
|
| domain | founded_year | HQ Location |
Italian company specializing in cardiology pharmaceuticals and clinical nutrition products.
|
|
| domain | founded_year | HQ Location |
Creates innovative supplements to support cardiovascular health.
|
|
| domain | founded_year | HQ Location |
Develops nutraceuticals to support cardiovascular health.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Provexis
Frequently Asked Questions about Provexis
When was Provexis founded?
Provexis was founded in 1999 and raised its 1st funding round 3 years after it was founded.
Where is Provexis located?
Provexis is headquartered in Reading, United Kingdom.
How many employees does Provexis have?
As of Mar 31, 2023, the latest employee count at Provexis is 2.
What is the annual revenue of Provexis?
Annual revenue of Provexis is $1.67M as on Mar 31, 2025.
What does Provexis do?
Provexis is engaged in manufacturing and marketing a tomato extract product that helps to reduce the propensity for aberrant blood clotting, typically associated with cardiovascular disease, which can lead to heart attack and stroke, The company sells the product under the brand Frutiflow. The extract is available in two formats, a syrup and a spray-dried powder and can be included in a broad range of food, beverage and dietary supplement. In June 2010, the company entered into a long-term alliance with DSM Nutritional Products to commercialise Frutiflow.
Who are the top competitors of Provexis?
Provexis's top competitors include GOLO, Cooke Pharma and Errekappa Euroterapici.
Is Provexis publicly traded?
Yes, Provexis is publicly traded on LSE under the ticker symbol PXS.
Who are Provexis's investors?
Provexis has 2 investors. Key investors include dsm-firmenich, and Enterprise Ventures.
What is Provexis's ticker symbol?
The ticker symbol of Provexis is PXS on LSE.